LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.
For more information about the financing please contact Ramgopal Rao, CEO at [email protected] and visit our website.
Thanks to the generosity of our sponsors, registration for our 2021 virtual forums is complimentary for all delegates.